Higgs P, Janda M, Asher R, ..., Obermair A. Pelvic floor functional outcomes after total abdominal vs total laparoscopic hysterectomy for endometrial cancer. Am J Obstet Gynecol. 2018 218(4):419.
Janda M, Armfield NR, Kerr G, ..., Obermair A. Surgical approach to hysterectomy and barriers to using minimally invasive methods. Aust N Z J Obstet Gynaecol. 2018 May 15.
Obermair H, Janda M, Obermair A. Real-world surgical outcomes of a gelatin-hemostatic matrix in women requiring a hysterectomy: A matched case-control study. Acta Obstet Gynecol Scand. 2016 May 20 [Epub ahead of print].
Khan S, et al. MicroRNA related polymorphisms and breast cancer risk. PLoS One. 2014;9(11):e109973.
Hedditch EL, et al. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst. 2014;106(7).
Gao B, et al.: Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci Rep. 2014;4:4669.
Dong Y, Loessner D, Irving-Rodgers H, Obermair A, Nicklin JL, Clements JA. Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis. 2014;31(1):135-47.
Healey CS, et al.: Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis. 2011;32(12):1862-6.
Fung JN, Seim I, Wang D, Obermair A, Chopin LK, Chen C. Expression and in vitro functions of the ghrelin axis in endometrial cancer. Horm Cancer. 2010;1(5):245-55.
Helland Å, ... Australian Ovarian Cancer Study Group,... et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One. 2011 Apr 13;6(4):e18064.Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC; Australian Cancer Study Group; Australian Ovarian Cancer Study Group. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer. 2008;44(16):2477-84.
Olsen CM, Nagle CM, Whiteman DC, Purdie DM, Green AC, Webb PM; Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group. Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer. 2008;123(2):450-6.
Ramus SJ, ... Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer. 2008;123(2):380-8.
Pearce CL, ... Australian Cancer Study; Australian Ovarian Cancer Study Group. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer. 2009;100(2):412-20.
Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. J Natl Cancer Inst. 2008;100(21):1519-29.
Schmid BC, Buluwela L, Liu QY, Fasching B, Tong D, Stimpfl M, Obermair A, Leodolter S, Zeillinger R. Expression of MUC1 splice variants correlates with invasive growth of breast cancer cell lines. Breast Cancer Res Treat 2002;76:211-219.
Bachtiary B, Obermair A, et al. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int J Cancer 2002;102:237-243.
Kohlberger, Muller-Klingspor, Heinzl H, Obermair A, et al. Prognostic value of laminin-5 in serous adenocarcinomas of the ovary. Anticancer Res 2002;22:3541-4.
Bachtiary B, Selzer E, Knocke TH, Poetter R, Obermair A. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett. 2002;179:197-203.
Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res. 2002;8:2253-2259
Obermair A, et al. Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 2002; 100: 166-171.
Csapo B, Szeles J, Helbich TH, Klarhoefer M, Balassy C, Pammer J, Obermair A. Histopathologic correlation of high resolution magnetic resonance imaging of human cervical tissue samples at 3 tesla: validation of technique. Invest Radiol 2002; 37: 381-385.
Tong D, Fabjani G, Heinze G, Obermair A, et al. Ananlysis Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer. 2001; 95: 394-397.
Obermair A, et al. Novel MUC1 splice variants are expressed in cervical carcinoma. Gynecol Oncol 2001; 83: 343-347.
Schindl M, Oberhuber G, Pichlbauer EG, Obermair A, et al. DNA Repair-Redox Enzyme Apurinic Endonuclease in Cervical Cancer: Evaluation of Redox-Control of HIF-1alpha and Prognostic Significance. Int J Oncol, 2001; 19: 799-802.
Muller-Klingspor V, Hefler L, Obermair A, et al. Prognostic value of beta1-integrin (=CD29) in serous adeneocarcinoma of the ovary. Anticancer Res 2001; 21: 2185-2188.
Schindl M, Oberhuber G, Obermair A, et al. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Research 2001; 61:5703-5706.
Birner P, Schindl M, Obermair A, et al. Expression of hypoxia-inducivle factor 1 alpha in epithelial ovarian tumours: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661-1668.
Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavourable prognosis in early-stage cervical cancer. Cancer Res 2000; 60: 4693-4696.
Schreiber S, Ackermann J, Obermair A, et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br J Haematol. 2000; 110: 605-609.
Obermair A, et al. Messenger RNA expression of MUC1 splice variants in epithelial ovarian cancer. Austral Asian J Cancer 2000; 1: 69-75.
Stimpfl M, Schmid BC, Obermair A, et al. Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood. Oncol Res 2000; 11: 367-373..
Stimpfl M, Schmid BC, Schiebel I, Tong D, Gitsch G, Leodolter S, Obermair A, Zeillinger R. Expression of mucins and cytokeratins in ovarian cancer cell lines: possible markers to detect disseminated ovarian cancer cells. Cancer Lett 1999; 145: 133-141.
Obermair A, et al. Vascular Endothelial Growth factor and its receptors in male fertility. Fertil Steril 1999; 72: 269-275.
Bancher-Todesca D, Gitsch G, Williams KE, Kohlberger P, Neunteufel W, Obermair A, et al. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecol Oncol 1998; 71: 59-63.
Reisenberger K, Egarter C, Schiebel I, Obermair A, et al. In vitro cytokine and prostaglandin production by amnion cells in the presence of bacteria. Am J Obstet Gynecol 1997; 176: 981-984.